Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2022 | ImPrint immune signature in 10,000 early-stage breast cancer from the real-world FLEX database

Adam Brufsky, MD, PhD, University of Pittsburgh, Pittsburgh, PA, talks on the ImPrint immune signature to predict response to immune checkpoint inhibitors (ICIs) in patients with breast cancer. The ImPrint signature was designed in tandem to the Phase II I-SPY (NCT01042379) trial, which explored neoadjuvant and personalized adaptive novel agents to treat breast cancer. Within this trial, several genomic signatures were found that correlated with response to various agents, including a 53 gene signature, ImPrint, that predicts pathologic complete response (pCR) to immune checkpoint inhibitors (ICIs). FLEX (NCT03053193) is an ongoing registry trial consisting of a group of 12,000 patients with early-stage breast cancer who received standard of care MammaPrint (MP) testing, that classifies patients as Low Risk or High Risk, with or without BluePrint (BP) molecular subtyping and consent to clinically annotated full genome data collection. The ImPrint signature was applied to the FLEX database. Patients who with HR-positive, high-risk breast cancer were predicted to have a significant response to ICIs. Patients with HER2-posistve breast cancer were predicted to have an 18-20% response rate to inhibitors. Patients with basal-like breast cancer were predicted to have a significant response to ICIs. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.